Expert Interview
Exploring the potential for Viking Therapeutics' VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Ticker(s): VKTXInstitution: Imperial College London
- Consultant Hepatologist at Imperial College Healthcare NHS Trust, and Honorary Senior Lecturer at Imperial College London.
- Leads the NAFLD service in the Trust, overseeing a clinic that cares for more than 600 patients.
- Research interests are focused in translational aspects of NAFLD care, including prediction of cardiovascular risk, quantitation of liver biopsies from NAFLD patients using machine learning, and management of NAFLD cirrhosis.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
